Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers

Journal of Clinical Investigation

Volumn 123, Issue 11, 2013, Pages 4935-4944

  Ricarte Filho, Julio C ^a   Li, Sheng ^b   Garcia Rendueles, Maria E R ^a   Montero Conde, Cristina ^a   Voza, Francesca ^a   Knauf, Jeffrey A ^a   Heguy, Adriana ^a   Viale, Agnes ^a   Bogdanova, Tetyana ^c   Thomas, Geraldine A ^d   Mason, Christopher E ^b   Fagin, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c V P Komisarenko Institute of Endocrinology and Metabolism of the Ukraine Academy of Medical Sciences   (Ukraine)

^d CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL KINASE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTROPHIC TYROSINE KINASE RECEPTOR TYPE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOTRANSFERASE; RNA; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS VARIANT 6; UNCLASSIFIED DRUG;

ARTICLE; CHERNOBYL ACCIDENT; CHILD; CHILDHOOD CANCER; CHROMOSOME REARRANGEMENT; COHORT ANALYSIS; CONTROLLED STUDY; GENE FUSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; RNA SEQUENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; THYROID CANCER; UKRAINE;

EID: 84887492828     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69766     Document Type: Article

References (32)

1. Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer. 2002; 2(7):543-549.
2. Cardis E, et al. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst. 2005; 97(10):724-732.
3. Bounacer A, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene. 1997;15(11):1263-1273.
4. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997; 57(9):1690-1694.
5. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene. 1995; 11(12):2459-2467.
6. Fugazzola L, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995;55(23):5617-5620.
7. Mizuno T, et al. Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene. 2000; 19(3):438-443.
8. Caudill CM, Zhu Z, Ciampi R, Stringer JR, Nikiforov YE. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab. 2005;90(4):2364-2369.
9. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science. 2000; 290(5489):138-141.
10. Roccato E, et al. Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Res. 2005; 65(7):2572-2576.
11. Santoro M, et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer. 2000; 82(2):315-322.
12. Rabes HM, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res. 2000;6(3):1093-1103.
13. Ciampi R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005; 115(1):94-101.
14. Asmann YW, et al. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res. 2011;39(15):e100.
15. Lui WO, et al. CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res. 2008;68(17):7156-7164.
16. Tognon C, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367-376.
17. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998; 18(2):184-187.
18. Koboldt DC, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568-576.
19. Pratilas CA, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A. 2009;106(11):4519-4524.
20. Giordano TJ, et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res. 2006; 12(7 pt 1):1983-1993.
21. Chen K, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods. 2009;6(9):677-681.
22. Roukos V, Burman B, Misteli T. The cellular etiology of chromosome translocations. Curr Opin Cell Biol. 2013;25(3):357-364.
23. Lannon CL, Sorensen PH. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin Cancer Biol. 2005; 15(3):215-223.
24. Haferlach C, et al. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012;51(4):328-337.
25. Martin MJ, et al. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol. 2006; 26(5):1754-1769.
26. Morrison KB, Tognon CE, Garnett MJ, Deal C, Sorensen PH. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene. 2002; 21(37):5684-5695.
27. Castro P, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):213-220.
28. Palos-Paz F, et al. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. Eur J Endocrinol. 2008; 159(5):623-631.
29. Sassolas G, et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid. 2012;22(1):17-26.
30. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569-580.
31. Ricarte-Filho JC, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69(11):4885- 4893.
32. Barrett T, et al. NCBI GEO: mining millions of expression profiles - database and tools. Nucleic Acids Res. 2005;33(Database issue):D562-D566.